01—Abstract
Summary
Summary of the 8-K filed October 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. reported strong third-quarter 2026 financial and operating results, demonstrating robust growth across its key product lines and pipeline advancements.
Total revenues surged by 36% year-over-year to $5.1 billiona, driven by significant increases in Dupixent, EYLEA HD, and Libtayo sales. This top-line growth translated into substantial bottom-line improvements, with GAAP EPS rising 35% to $18.45 and non-GAAP EPS jumping 70% to $20.07. The company also highlighted progress in its pipeline, including the FDA approval of Pasatru™ (garetosmab) for fibrodysplasia ossificans progressiva (FOP) and positive developments for Libtayo's dosing schedule and indications.
Furthermore, Regeneron expanded its collaboration with Sanofi, securing a $1.0 billionb upfront payment and potential for additional milestones, signaling confidence in future long-acting immunology antibody developments. These results position Regeneron for a strong year and underscore the continued commercial success and pipeline productivity of the company.
02—Key points
Key Highlights
- Total revenues increased by 36% to $5.1 billion in Q3 2026 compared to Q3 2025.
- Dupixent global net sales (recorded by Sanofi) grew 35% to $6.5 billion.
- EYLEA HD U.S. net sales saw a significant increase of 62% to $699 million.
- Libtayo global net sales increased by 51% to $550 million.
- GAAP EPS rose 35% to $18.45, and non-GAAP EPS increased by 70% to $20.07.
- Pasatru™ (garetosmab) received FDA approval for fibrodysplasia ossificans progressiva (FOP).
- Regeneron expanded its collaboration with Sanofi, receiving a $1.0 billion up-front payment for next-generation immunology antibodies, with potential for up to $7.0 billion in future milestones.
03—Questions
Frequently Asked Questions
What were the main drivers of Regeneron's revenue growth in Q3 2026?
The primary drivers of Regeneron's revenue growth were strong performance from key products, notably Dupixent, EYLEA HD, and Libtayo, which all achieved record net sales. Increased collaboration revenue from Sanofi, particularly due to higher profits from antibody commercialization and the full repayment of the Development Balance, also significantly contributed to the 36% year-over-year revenue increase.
Can you elaborate on the expansion of the Sanofi collaboration?
Regeneron expanded its antibody collaboration with Sanofi to include multiple next-generation, long-acting immunology antibodies. This strategic move resulted in a $1.0 billion upfront payment to Regeneron, which will be recognized as collaboration revenue in the fourth quarter of 2026. The agreement also includes potential for up to an additional $7.0 billion in future milestone payments. Both companies will share development and commercialization costs and future profits equally.
What is the significance of the FDA approval for Pasatru™ (garetosmab)?
The FDA approval of Pasatru™ (garetosmab) for fibrodysplasia ossificans progressiva (FOP) marks a significant pipeline advancement. This approval allows Pasatru to reduce the formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP, addressing a rare and serious genetic disorder.
How did EYLEA sales perform, and what is the outlook given the transition to EYLEA HD?
EYLEA HD U.S. net sales increased significantly by 62% to $699 million in Q3 2026. While EYLEA U.S. net sales decreased by 41% to $400 million, this was primarily due to lower sales volumes as patients continue to transition to the newer EYLEA HD. The combined U.S. sales of EYLEA HD and EYLEA saw a slight decrease of 1% in Q3 2026 compared to Q3 2025, but the strong growth of EYLEA HD indicates a successful product transition.
04—Continue